A pilot study of the effect of rivaroxaban in sickle cell anemia.

Kenneth I AtagaLaila ElsherifDavid WichlanAdane F WoguNeil MatsuiRafal PawlinskiJianwen CaiNigel S Key

Published in: Transfusion (2021)

Rivaroxaban was safe but did not significantly decrease coagulation activation, endothelial activation, or inflammation. Rivaroxaban did not improve microvascular blood flow. Adequately powered studies are required to further evaluate the efficacy of rivaroxaban in SCD. Clinicaltrials.gov Identifier: NCT02072668.

Keyphrases

venous thromboembolism
atrial fibrillation
blood flow
pulmonary embolism
oxidative stress
chronic kidney disease
endothelial cells
case control